{"id":"W3167584894","doi":"10.1200/jco.2021.39.15_suppl.5574","title":"Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Cancer Care Ontario; McMaster University; University of Toronto; Royal Victoria Hospital; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"Conquer Cancer Foundation","keywords":"Medicine; PTEN; Olaparib; Clinical endpoint; Oncology; Internal medicine; Endometrial cancer; Biomarker; Cohort; Serous fluid; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; PI3K/AKT/mTOR pathway; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001867623,0.001390957,0.00201169,0.0003972178,0.000351641,0.0009428657,0.0009720728,0.00153781,0.005641422],"category_scores_gemma":[0.001124685,0.000705805,0.001322961,0.0003761847,0.0008477152,0.0006707282,0.0003793958,0.002601517,0.00126292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009178533,"about_ca_system_score_gemma":0.001790846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001080254,"about_ca_topic_score_gemma":0.00289622,"domain_scores_codex":[0.9995288,0.0002518042,0.00002679809,0.00008274538,0.00002872108,0.00008114045],"domain_scores_gemma":[0.9993526,0.0001226,0.0001205212,0.00006591498,0.0000347225,0.0003036209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8905329,0.03466131,0.002377795,0.0008457612,0.0008443162,0.0001950577,0.0001294314,0.001218272,0.01919176,0.0002116768,0.002944506,0.04684717],"study_design_scores_gemma":[0.7240483,0.2692191,0.003128242,0.00002545287,0.0002521202,0.0001513075,0.00002592603,0.000518019,0.001096686,0.0001218124,0.001399661,0.00001336269],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836897,0.003578298,0.0005454515,0.0007040216,0.0002889832,0.006645571,0.001939819,0.0001521873,0.002455835],"genre_scores_gemma":[0.9804642,0.002095797,0.001912393,0.001316749,0.0002309605,0.006004406,0.003226603,0.0000307464,0.004718239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005641422,"threshold_uncertainty_score":0.01887244,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2521662109518682,"score_gpt":0.5363523493509751,"score_spread":0.2841861383991069,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}